Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference

Rhea-AI Summary

Pear Therapeutics, Inc. (Nasdaq: PEAR) will participate in Cowen’s 7th Annual FutureHealth Conference on June 22-23, 2022. CEO Corey McCann will engage in a panel discussion titled, “Commercializing Prescription Digital Therapeutics,” on June 23 at 12:40 p.m. ET. Pear Therapeutics specializes in developing prescription digital therapeutics (PDTs) to enhance patient care, clinician engagement, and cost-effectiveness for payers. Their notable products include reSET®, reSET-O®, and Somryst®, addressing substance use disorder, opioid use disorder, and chronic insomnia, respectively.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Cowen’s 7th Annual FutureHealth Conference, a virtual event taking place June 22 – June 23, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a panel discussion titled, “Commercializing Prescription Digital Therapeutics,” on Thursday, June 23 at 12:40 p.m. ET. To listen to the live event, please contact your Cowen representative with interest.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005155/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

When will Pear Therapeutics participate in the Cowen FutureHealth Conference?

Pear Therapeutics will participate in the Cowen FutureHealth Conference on June 22-23, 2022.

Who will represent Pear Therapeutics at the conference?

CEO Corey McCann will represent Pear Therapeutics at the conference.

What is the topic of the panel discussion by Pear Therapeutics?

The panel discussion topic is “Commercializing Prescription Digital Therapeutics.”

What date and time is Pear Therapeutics' panel discussion scheduled?

The panel discussion is scheduled for June 23, 2022, at 12:40 p.m. ET.

What are the key products developed by Pear Therapeutics?

Pear Therapeutics has developed products including reSET®, reSET-O®, and Somryst® for various health conditions.